Adicet Bio, Inc. ACET
We take great care to ensure that the data presented and summarized in this overview for Adicet Bio, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ACET
View all-
Orbimed Advisors LLC San Diego, CA11.4MShares$8.13 Million0.25% of portfolio
-
Tang Capital Management LLC San Diego, CA8.22MShares$5.84 Million0.3% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.54MShares$5.35 Million0.1% of portfolio
-
Goldman Sachs Group Inc New York, NY3.75MShares$2.66 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.27MShares$2.32 Million0.0% of portfolio
-
Carlyle Group Inc. Washington, DC2.95MShares$2.09 Million2.23% of portfolio
-
Abingworth LLP London, X02.12MShares$1.5 Million6.27% of portfolio
-
Acadian Asset Management LLC Boston, MA2.07MShares$1.47 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY1.88MShares$1.33 Million0.01% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny1.15MShares$819,2090.0% of portfolio
Latest Institutional Activity in ACET
Top Purchases
Top Sells
About ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Insider Transactions at ACET
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 11
2025
|
Lloyd Klickstein |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+5.15%
|
-
|
|
Jun 11
2025
|
Katie Peng |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+33.33%
|
-
|
|
Jun 11
2025
|
Steve Dubin |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+20.63%
|
-
|
|
Jun 11
2025
|
Jeffrey Chodakewitz |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+25.0%
|
-
|
|
Jun 11
2025
|
Andrew Sinclair |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+25.0%
|
-
|
|
Jan 24
2025
|
Blake Aftab Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,270
-10.03%
|
$0
$0.92 P/Share
|
|
Jan 24
2025
|
Don Healey Chief Technology Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,560
-11.83%
|
$0
$0.92 P/Share
|
|
Jan 24
2025
|
Chen Schor President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
28,101
-17.0%
|
$0
$0.92 P/Share
|
|
Jan 24
2025
|
Brian Nicholas Harvey Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,752
-8.77%
|
$0
$0.92 P/Share
|
|
Jun 05
2024
|
Michael Kauffman |
SELL
Open market or private sale
|
Direct |
5,900
-50.0%
|
$5,900
$1.43 P/Share
|
|
Jun 05
2024
|
Michael Kauffman |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+33.33%
|
-
|
|
Jun 05
2024
|
Steve Dubin |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+25.99%
|
-
|
|
Jun 05
2024
|
Aya Jakobovits |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+33.33%
|
-
|
|
Jun 05
2024
|
Jeffrey Chodakewitz |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+33.33%
|
-
|
|
Jun 05
2024
|
Carl L Gordon |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+33.33%
|
-
|
|
Jun 05
2024
|
Andrew Sinclair |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+33.33%
|
-
|
|
Jun 05
2024
|
Katie Peng |
BUY
Grant, award, or other acquisition
|
Direct |
5,900
+50.0%
|
-
|
|
Jan 25
2024
|
Carl L Gordon |
BUY
Open market or private purchase
|
Indirect |
3,125,000
+28.21%
|
$6,250,000
$2.4 P/Share
|
|
Jan 25
2024
|
Orbimed Advisors LLC |
BUY
Open market or private purchase
|
Indirect |
3,125,000
+28.21%
|
$6,250,000
$2.4 P/Share
|
|
Jan 24
2024
|
Blake Aftab Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,700
+23.96%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 29.5K shares |
|---|
| Payment of exercise price or tax liability | 51.7K shares |
|---|